Previous 10 | Next 10 |
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of John Hohneker, M.D., to its Board of Directors. “John is...
Gainers: [[ISBC]] +13.2%. [[RDUS]] +8.6%. [[SRGA]] +8.5%. [[ARAY]] +8.3%. [[GOOG]] +7.8%.Losers: [[TENB]] -10.6%. [[VYGR]] -6.3%. [[TLSA]] -5.3%. [[EVLO]] -4.6%. [[RAIL]] -4.5%. For further details see: ARAY, GOOG, TENB and RDUS among after-hours movers
Evelo Biosciences (EVLO) has priced its public offering of 4.5M common shares at $15.00/share, for expected gross proceeds of ~$67.5M.Underwriters' over-allotment is an additional 675K shares. Net proceeds will be used to develop and advance product candidates, for R&D activities and for ...
Clinical stage biotech Evelo Biosciences (EVLO) announced that it intends to offer and sell $50M shares in an underwritten public offering.Evelo expects to grant the underwriters a 30-day option to purchase up to an additional $7.5M.The company intends to use proceeds to continue the dev...
Evelo Biosciences (EVLO) is up ~9.8% after announcing new positive confirmatory data following the completion of mild and moderate atopic dermatitis cohort in its Phase 1b clinical trial evaluating the safety and tolerability of EDP1815.With no treatment-related adverse events of moderat...
–EDP1815 was well tolerated, and showed clinically meaningful and consistent changes in all measured physician-reported outcomes – –Improvements in patient-reported outcomes in DLQI and POEM, including itch– –EASI50 benchmark reached ...
Evelo Biosciences ([[EVLO]] +4.2%) plans to expand Phase 2 trial evaluating EDP1815, its lead anti-inflammatory product candidate in mild to moderate psoriasis, and include atopic dermatitis. Enrollment of psoriasis patients was completed in December.The company plans to accelerate ...
-- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial to 2Q 2021; full dataset expected 2H 2021 -- -- Advance novel anti-inflammat...
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced the appointment of J...
Gainers: Nxt-ID (NXTD) +50%.Diginex (EQOS) +48%.Aethlon Medical (AEMD) +40%.MIND Technology (MIND) +27%.Aclaris Therapeutics (ACRS) +24%.Tilray (TLRY) +23%.MiMedx Group (MDXG) +22%.Amyris (AMRS) +21%.Drive Shack (DS) +20%.Marathon Patent Group (MARA) +19%.Losers: Concord Medical Services...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...